<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05050942</url>
  </required_header>
  <id_info>
    <org_study_id>HS-19-657</org_study_id>
    <secondary_id>2021-000849-40</secondary_id>
    <nct_id>NCT05050942</nct_id>
  </id_info>
  <brief_title>A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET</brief_title>
  <acronym>SORENTO</acronym>
  <official_title>A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Camurus AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Camurus AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide&#xD;
      LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who&#xD;
      experience progressive disease in the randomized part of the study may proceed to an&#xD;
      open-label extension part with intensified treatment with CAM2029.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) as assessed by a Blinded Independent Review Committee (BIRC)</measure>
    <time_frame>From date of randomization until disease progression or death due to any cause, whichever comes first, assessed up to 48 months</time_frame>
    <description>PFS is defined as time from the date of randomization to the date of the first documented disease progression as per RECIST 1.1 or death due to any cause (whichever occurs first)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years following the primary efficacy analysis</time_frame>
    <description>The time from the date of randomization to the date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS as assessed by local Investigators</measure>
    <time_frame>From date of randomization until disease progression or death due to any cause, whichever comes first, assessed up to 48 months</time_frame>
    <description>PFS is defined as time from the date of randomization to the date of the first documented disease progression as per RECIST 1.1 or death due to any cause (whichever occurs first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>From date of randomization until disease progression, assessed up to 48 months</time_frame>
    <description>The proportion of patients with best overall response of complete response (CR) or partial response (PR), as per BIRC according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>From date of randomization until disease progression, assessed up to 48 months</time_frame>
    <description>The proportion of patients with a best overall response of CR, PR or stable disease (SD), as per BIRC according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor response</measure>
    <time_frame>From date of randomization until disease progression, assessed up to 48 months</time_frame>
    <description>The time from the date of randomization to the first documented response of CR or PR, as per BIRC according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>From date of randomization until disease progression or death due to underlying cancer, whichever comes first, assessed up to 48 months</time_frame>
    <description>The time from the date of the first documented response of CR or PR to the date of the first documented progression or death due to underlying cancer, as per BIRC according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>From screening to the safety follow-up, assessed up to 6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Gastro-enteropancreatic Neuroendocrine Tumor</condition>
  <arm_group>
    <arm_group_label>CAM2029</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Octreotide LAR or lanreotide ATG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAM2029</intervention_name>
    <description>CAM2029 (octreotide subcutaneous depot) 20 mg will be administered every 2 weeks as a subcutaneous injection</description>
    <arm_group_label>CAM2029</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Octreotide LAR</intervention_name>
    <description>Octreotide LAR 30 mg will be administered every 4 weeks as an intramuscular injection</description>
    <arm_group_label>Octreotide LAR or lanreotide ATG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanreotide ATG</intervention_name>
    <description>Lanreotide ATG 120 mg will be administered every 4 weeks as a deep subcutaneous injection</description>
    <arm_group_label>Octreotide LAR or lanreotide ATG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patient ≥18 years old&#xD;
&#xD;
          -  Histologically confirmed, advanced (unresectable and/or metastatic), and&#xD;
             well-differentiated NET of GEP or presumed GEP origin&#xD;
&#xD;
          -  At least 1 measurable, somatostatin receptor-positive lesion according to RECIST 1.1&#xD;
             determined by multiphasic CT or MRI (performed within 28 days before randomization)&#xD;
&#xD;
          -  ECOG performance status of 0 to 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented evidence of disease progression while on treatment (including SSAs) for&#xD;
             locally advanced unresectable or metastatic disease&#xD;
&#xD;
          -  Known central nervous system metastases&#xD;
&#xD;
          -  Consecutive treatment with long-acting SSAs for more than 6 months before&#xD;
             randomization&#xD;
&#xD;
          -  Carcinoid symptoms that are refractory to treatment (according to the Investigator's&#xD;
             judgement) with conventional doses of octreotide LAR or lanreotide ATG and/or to&#xD;
             treatment with daily doses of ≤600 µg of octreotide IR&#xD;
&#xD;
          -  Previous treatment with more than 1 cycle of targeted therapies such as mTOR&#xD;
             inhibitors or vascular endothelial growth factor inhibitors, or more than 1 cycle of&#xD;
             chemotherapy or interferon for GEP-NET&#xD;
&#xD;
          -  Treatment of GEP-NET with trans-arterial chemoembolization or trans-arterial&#xD;
             embolization within 12 months before screening&#xD;
&#xD;
          -  Previously received radioligand therapy (PRRT) at any time&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simron Singh, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Camurus AB</last_name>
    <phone>+46 46 286 57 30</phone>
    <email>info@camurus.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Halperin</last_name>
    </contact>
    <investigator>
      <last_name>Daniel Halperin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS - Istituto Nazionale dei Tumori di Napoli Fondazione G. Pascale - Oncologia Addominale</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Salvatore Tafuto</last_name>
    </contact>
    <investigator>
      <last_name>Salvatore Tafuto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron - Vall d'Hebron Institut d'Oncologia (VHIO)</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jaume Capdevila</last_name>
    </contact>
    <investigator>
      <last_name>Jaume Capdevila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidad Autonoma de Madrid (UAM) - Facultad de Medicina - Hospital Universitario Fundacion Jimenez Diaz (UAM-FJD) (Clinica de la Concepcion)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Caramés Sanchez</last_name>
    </contact>
    <investigator>
      <last_name>Cristina Caramés Sanchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidad Autonoma de Madrid (UAM) - Hospital Universitario La Paz (HULP)</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Custodio</last_name>
    </contact>
    <investigator>
      <last_name>Ana Custodio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidad de Cantabria (UC) - Hospital Universitario Marques de Valdecilla (HUMV)</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Lopez Lopez</last_name>
    </contact>
    <investigator>
      <last_name>Carlos Lopez Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 21, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAM2029</keyword>
  <keyword>GEP-NET</keyword>
  <keyword>Octreotide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Lanreotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

